Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

被引：12
|
作者：
Trudel, Suzanne [1 ]
McCurdy, Arleigh [2 ]
Fu, Molei [3 ]
Sutherland, Heather J. [4 ]
Louzada, Martha L. [5 ]
Chu, Michael P. [6 ]
White, Darrell J. [7 ,8 ]
Mian, Hira S. [9 ]
Kotb, Rami [10 ]
Othman, Ibraheem [11 ]
Kardjadj, Moustafa [12 ]
Gul, Engin [13 ]
Reece, Donna E. [3 ]
机构：
[1] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[2] Ottawa Hosp, Dept Med, Div Hematol, Ottawa, ON, Canada
[3] Canadian Myeloma Res Grp CMRG, Vaughan, ON, Canada
[4] Vancouver Gen Hosp, Div Hematol, Vancouver, BC, Canada
[5] Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada
[6] Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada
[7] Dalhousie Univ, Halifax, NS, Canada
[8] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[9] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[10] CancerCare Manitoba, Dept Med Oncol & Hematol, Winnipeg, MB, Canada
[11] Saskatchewan Canc Agcy, Allan Blair Canc Ctr, Regina, SK, Canada
[12] Canadian Myeloma Res Grp, Toronto, ON, Canada
[13] Canadian Myeloma Res Grp CMRG, Concord, ON, Canada
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-160445
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7306 / 7307
页数：2
相关论文
共 50 条
  • [31] Phase I/II Study of Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone (BelCyd) in Relapsed/Refractory Multiple Myeloma
    Badros, Ashraf Z.
    Nash, Thea
    Lawrance, Christopher
    Tittle, Brandon
    Philip, Sunita
    Sunshine, Sarah
    Munir, Wuqaas
    Fan, Xiaoxuan
    Ide, Christina
    Atanackovic, Djordje
    BLOOD, 2023, 142
  • [32] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Schlossman, Robert L.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Reimonn, Cassandra A.
    Andrade, Danielle X.
    Redd, Robert
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
  • [33] Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
    Matsue, Kosei
    Iwasaki, Hiromi
    Chou, Takaaki
    Tobinai, Kensei
    Sunami, Kazutaka
    Ogawa, Yoshiaki
    Kurihara, Mari
    Midorikawa, Shuichi
    Zaki, Mohamed
    Doerr, Thomas
    Iida, Shinsuke
    CANCER SCIENCE, 2015, 106 (11): : 1561 - 1567
  • [34] Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
    Trudel, Suzanne
    Beksac, Meral
    Pour, Ludek
    Delimpasi, Sosana
    Quach, Hang
    Vorobyev, Vladimir I.
    Cavo, Michele
    Suzuki, Kazuhito
    Robak, Pawel
    Morris, Kristin
    Phillips-Jones, Amy
    Zhou, Xiaoou Linnette
    Fulci, Giulia
    Sule, Neal
    Kremer, Brandon
    Opalinska, Joanna
    Mateos, Maria-Victoria
    Dimopoulos, Meletios Athanasios
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA105 - LBA105
  • [35] Combination of ixazomib, pomalidomide and dexamethasone in the treatment of multiple myeloma in relapse and refractory to lenalidomide
    Stocker, Nicolas
    HEMATOLOGIE, 2018, 24 (04): : 261 - 262
  • [36] The Combination of Isatuximab with Pomalidomide and Dexamethasone in Second Line Relapse and Refractory Multiple Myeloma
    Bobin, Arthur
    Soufyane, Ennebet
    Guidez, Stephanie
    Chacon, Aurelia
    Gardeney, Helene
    Basle, Caroline
    Dindinaud, Elodie
    Douma, Soukaina
    Roul, Christophe
    Corby, Anne
    Motard, Carine
    Olivier, Gaelle
    Denis, Guillaume
    Vinson, Camille
    Tomowiak, Cecile
    Gruchet, Cecile
    Moya, Niels
    Mocquot, Pauline
    Dessane, Berangere
    Boscagli, Annick
    Perrot, Aurore
    Leleu, Xavier
    BLOOD, 2024, 144 : 7041 - 7042
  • [37] Pomalidomide-dexamethasone combination is efficient in lenalidomide-refractory multiple myeloma
    Coman, Tereza
    HEMATOLOGIE, 2010, 16 (06): : 410 - 411
  • [38] Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
    Beksac, Meral
    Garcia, Esther Gonzalez
    Delimpasi, Sosana
    Robak, Pawel
    Karunanithi, Kamaraj
    De Arriba, Felipe
    Radocha, Jakub
    Kim, Kihyun
    Voloshin, Sergey
    Zherebtsova, Vera
    Osipov, Iurii
    Mateos, Maria-Victoria
    Zafar, Syed F.
    Pour, Ludek
    Spicka, Ivan
    Suzuki, Kazuhito
    Du, Xin
    Wilkes, Jodie
    Maroj, Brijesh
    Morris, Kristin
    Ma, Jie
    Polinkovsky, Margaret
    Wang, Zhaohui
    Zhou, Xiaoou L.
    Fulci, Giulia
    Sule, Neal
    Kremer, Brandon
    Opalinska, Joanna
    Trudel, Suzanne
    Dimopoulos, Meletios A.
    BLOOD, 2024, 144 : 4731 - 4733
  • [39] DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B- Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Trudel, Suzanne
    Davis, Randy
    Lewis, Nicole M.
    Bakshi, Kalpana K.
    Chopra, Bikramjit
    de Oca, Rocio Montes
    Ferron-Brady, Geraldine
    Eliason, Laurie
    Kremer, Brandon E.
    Gupta, Ira
    Wu, Frank S.
    BLOOD, 2020, 136
  • [40] Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma
    De Oca, Rocio Montes
    Gupta, Ira
    Shelton, Chris
    CANCER RESEARCH, 2020, 80 (16)
12345